巴基斯坦消除乙型和丙型肝炎的障碍与策略
该研究基于世界卫生组织2020年估计、区域行动计划中期审查问卷和免疫接种估计数据,分析巴基斯坦乙型和丙型肝炎的疾病负担及治理、政策、战略信息和服务提供等领域的应对情况。结果显示乙肝普通人群患病率1.6%,每年12000例死亡;丙肝患病率7.5%,每年19000例死亡和545000例新发病例,仅22%丙肝病例被诊断、2%接受治疗。作者认为按当前速度消除肝炎似乎不可能。
要点
- 巴基斯坦乙肝普通人群患病率1.6%,每年12000例死亡;丙肝患病率7.5%,每年19000例死亡和545000例新发病例。
- 乙肝疫苗接种覆盖率74%,仅3%新生儿接种乙肝疫苗首剂;丙肝仅22%病例被诊断、2%接受治疗,治疗应答率96%。
- 作者认为按当前速度消除肝炎似乎不可能;引入乙肝疫苗首剂、提高检测可及性和可负担性可改善检测和治疗人数。
核心结论
- 巴基斯坦肝炎疾病负担最高,按当前速度消除肝炎似乎不可能。
- 引入乙肝疫苗首剂以及改善检测的可及性和可负担性可改善检测和治疗人数。
- 需要从国内和国外动员资金以支持疾病消除。
研究设计与样本
- 研究收集世界卫生组织2020年估计、世界卫生组织区域行动计划中期审查问卷和世界卫生组织免疫接种估计数据进行分析。
- 分析涵盖疾病负担(患病率和死亡率)以及治理、政策与财务、战略信息、服务提供三个主题领域的应对情况。
主要发现
- 乙肝普通人群患病率1.6%,每年12000例死亡;丙肝普通人群患病率7.5%,每年19000例死亡和545000例新发病例。
- 治理指标总体良好,有 focal point、国家肝炎战略、行动计划、降价战略和民间社会参与,但缺少成本核算行动计划和倡导战略。
- 政策和指南指标得到充分处理,有乙肝和丙肝检测和治疗指南、筛查所有献血的政策和注射安全政策,但缺少及时乙肝疫苗首剂接种政策和弱势人群乙肝疫苗接种政策。
- 战略信息的两项指标(关键肝炎指标测量和定期数据审查)均缺失。
- 乙肝疫苗接种覆盖率74%,仅3%新生儿接种乙肝疫苗首剂;丙肝仅22%病例被诊断、2%接受治疗,治疗应答率96%。
关键数值与推荐
- 乙肝普通人群患病率1.6%,每年12000例死亡。
- 丙肝普通人群患病率7.5%,每年19000例死亡和545000例新发病例(发病率)。
- 乙肝疫苗接种覆盖率74%,新生儿乙肝疫苗首剂接种率3%。
- 丙肝病例诊断率22%,治疗率2%,治疗应答率96%。
临床怎么用
- 丙肝同日检测和治疗减少了总体脱失率并改善了照护 cascade。
- 分散化和任务转移是改善服务提供和覆盖社区的重要工具。
- 实施肝炎消除的财务是主要障碍。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pakistan has a high hepatitis burden for both hepatitis C virus (HCV) and hepatitis B virus (HBV). To achieve World Health Organization (WHO) 2030 targets for hepatitis elimination, there is a need to constitute progress in the country, find the barriers and strategies for HCV elimination, and take actions to address the gaps. METHODS: We collected data from (1) WHO estimates in 2020, (2) midterm review questionnaire of the WHO regional action plan, and (3) WHO estimates on immunization. We analyzed these data to inform (1) the burden defined as prevalence and mortality and (2) response in 3 thematic areas: governance, policy, and finance; strategic information; and service delivery. RESULTS: The prevalence of hepatitis B in the general population is 1.6% with 12 000 deaths/year. The prevalence of hepatitis C in the general population is 7.5% with 19 000 deaths and 545 000 new cases (incidence)/year. The selected indicators to monitor progress on viral hepatitis in Pakistan were governance and financing, policies and guidelines, and strategic information. The overall governance indicators are good with a focal point, a national hepatitis strategy, an operational plan, strategy for price reduction, and involvement of civil society but the costed action plan and the advocacy strategy are missing. The indicators on policies and guidelines are also adequately addressed. The hepatitis B and C testing and treatment guidelines are available, there is a policy to screen all blood donations, and there is an injection safety policy, but the policy for timely hepatitis B vaccine birth dose and hepatitis B vaccination for the vulnerable is missing. Both indicators regarding strategic information, that is measures of key hepatitis indicators and regular data review, are missing. The status of 5 key interventions in Pakistan show that the hepatitis B vaccination coverage is 74% and only 3% of newborn children are given the hepatitis B vaccine birth dose. Only 22% of HCV cases have been diagnosed and 2% have received treatment. Treatment response is 96%. Same-day testing and treatment of hepatitis C reduced the overall dropout rate and improved the cascade of care. Decentralization and task shifting are important tools to improve service delivery and reach communities. Finances to implement hepatitis elimination is a major barrier. CONCLUSIONS: Pakistan has the highest hepatitis disease burden. With the current pace, hepatitis elimination appears impossible. Introduction of the birth dose of hepatitis B vaccine and improving access and affordability of testing can improve the testing and treatment numbers. Finances need to be mobilized from within the country and outside to support disease elimination.
引用
- Qureshi H, Mahmood H, Sabry A, et al. Barriers and Strategies for Hepatitis B and C Elimination in Pakistan. J Infect Dis. 2023. PMID: 37703344. doi:10.1093/infdis/jiad022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。